[go: up one dir, main page]

WO2017021974A3 - Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts - Google Patents

Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts Download PDF

Info

Publication number
WO2017021974A3
WO2017021974A3 PCT/IN2015/000338 IN2015000338W WO2017021974A3 WO 2017021974 A3 WO2017021974 A3 WO 2017021974A3 IN 2015000338 W IN2015000338 W IN 2015000338W WO 2017021974 A3 WO2017021974 A3 WO 2017021974A3
Authority
WO
WIPO (PCT)
Prior art keywords
lysolecithin
lecithin
solubility
extracts
hydrophobic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2015/000338
Other languages
French (fr)
Other versions
WO2017021974A8 (en
WO2017021974A2 (en
Inventor
Ganga Raju Gokaraju
Rama Raju Gokaraju
Kiran Bhupathiraju
Trimurtulu Golakoti
Ravichandran Sripathy
Nirvanashetty Somashekara
Ramchand Nanappan Chaniyilparampu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Pharmaceuticals Pvt Ltd
Original Assignee
Laila Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Pharmaceuticals Pvt Ltd filed Critical Laila Pharmaceuticals Pvt Ltd
Priority to PCT/IN2015/000338 priority Critical patent/WO2017021974A2/en
Publication of WO2017021974A2 publication Critical patent/WO2017021974A2/en
Anticipated expiration legal-status Critical
Publication of WO2017021974A8 publication Critical patent/WO2017021974A8/en
Publication of WO2017021974A3 publication Critical patent/WO2017021974A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition de molécule(s) et/ou d'extrait(s) hydrophobe(s) d'origine végétale ayant une biodisponibilité améliorée comprenant un mélange synergique actif hydrophobe et lécithine et lysolécithine et son procédé de préparation.The present invention relates to a composition of molecule (s) and / or hydrophobic extract (s) of plant origin having improved bioavailability comprising a hydrophobic active synergistic mixture and lecithin and lysolecithin and its preparation process.

PCT/IN2015/000338 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts Ceased WO2017021974A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Publications (3)

Publication Number Publication Date
WO2017021974A2 WO2017021974A2 (en) 2017-02-09
WO2017021974A8 WO2017021974A8 (en) 2018-03-08
WO2017021974A3 true WO2017021974A3 (en) 2019-01-17

Family

ID=57944200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000338 Ceased WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Country Status (1)

Country Link
WO (1) WO2017021974A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018179011A1 (en) * 2017-03-29 2018-10-04 Olene Life Sciences Private Limited Composition to enhance bioavailability of natural compounds
CN110025604A (en) * 2019-04-11 2019-07-19 中国科学院西北高原生物研究所 Purposes of the hypericin in the Related product that preparation inhibits glucosidase activity
CN115813780B (en) * 2022-03-30 2024-08-13 广东格烯生物科技股份有限公司 Nano-scale yellow-removing composition containing tetrahydrocurcumin and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20100137252A1 (en) * 2008-12-02 2010-06-03 Yasuko Matsumura Ophthalmic composition
US20110065662A1 (en) * 2009-07-24 2011-03-17 Amazentis Sa Compounds, Compositions, and Methods for Protecting Brain Health in Neurodegenerative Disorders
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20100137252A1 (en) * 2008-12-02 2010-06-03 Yasuko Matsumura Ophthalmic composition
US20110065662A1 (en) * 2009-07-24 2011-03-17 Amazentis Sa Compounds, Compositions, and Methods for Protecting Brain Health in Neurodegenerative Disorders
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Also Published As

Publication number Publication date
WO2017021974A8 (en) 2018-03-08
WO2017021974A2 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
MA42678B1 (en) NEW SUBSTITUTED NUCLEOSIDE ANALOGS WITH BICYCLIC AROMATIC CYCLE 6-6 FOR USE AS PRMT5 INHIBITORS
MA38289A1 (en) Pharmaceutical composition with improved bioavailability
EA201990495A1 (en) BIARY COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
MA43409B1 (en) Polycyclic compounds for use as bruton tyrosine kinase inhibitors
EA201990221A1 (en) 1,3-DIHYDROXIPHENYL DERIVATIVES APPLICABLE AS IMMUNOMODULATORS
BR112015023948A2 (en) compound of formula (i), pharmaceutical composition, method for treating and / or preventing a proliferative disease and for inhibiting or differentiating growth of a cancer stem cell
BR112019001253A2 (en) compound, pharmaceutical composition, and methods of treating cancer or muscle atrophy and parkinson's disease.
EA201690386A1 (en) COMPOUNDS AND COMPOSITIONS AS MEK INHIBITORS
BR112013028430A2 (en) compound, pharmaceutical composition, method for treating a spleen tyrosine kinase (syk) mediated disease or condition, and use of a therapeutically efficient amount of the compound
FR2938439B1 (en) EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON
UY34955A (en) 4-METHYL-2,3,5,9,9B-PENTAAZA-CICLOPENTA [A] NAFTALENOS
EA201170289A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AT LOW CONCENTRATION OF IMPURITIES
EA202091372A1 (en) PYRROLO (PYRAZOLO) PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR
MX391440B (en) NOVEL HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT.
WO2017021974A3 (en) Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts
EA201791432A1 (en) COMPOSITIONS ON THE BASIS OF MONOMETHYLATE PREPARATION
EA202090900A1 (en) IMMUNOPROTEASOM INHIBITORS
WO2013192517A3 (en) Compounds for treating infectious diseases
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
BR112022010441A2 (en) EQUINOCANDIN ANALOGS AND PREPARATION METHOD FOR THEM
CO2018003756A2 (en) Pyrazolo [1,5-a] pyrimidin-3-carboxyamide cyclic ether derivatives
BR112018015191A2 (en) 6,7-dihydro-5h-pyrazolo [5,1-b] [1,3] oxazine-2-carboxamide compounds
MA41174B1 (en) Imidazopyridazine derivatives used as pi3kbeta inhibitors
FR2914146B1 (en) PROCESS FOR THE NEMATOCIDAL TREATMENT OF PLANTS BASED ON EUGENOL AND LECITHIN (S) AND / OR DERIVATIVES
NZ760781A (en) Process for the preparation of standardized composition of arjunoglucoside from the bark of terminalia arjuna

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2